All Stories

  1. Cross-Sectional Multicenter Biomonitoring Study on Genotoxicity and Oxidative DNA Damage in Oncology Healthcare Workers from Seven Italian Hospitals

    Article • Journal of Xenobiotics, January 2026, MDPI AG

    Dr Paolo PB Baldo

  2. Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer

    Article • Current Oncology, October 2025, MDPI AG

    Dr Paolo PB Baldo

  3. Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)

    Article • Cancers, May 2024, MDPI AG

    Dr Marco Chiumente, Dr Paolo PB Baldo

  4. Real World Safety and Outcome of First Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)

    Article • April 2024, MDPI AG

    Dr Marco Chiumente, Dr Paolo PB Baldo

  5. Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance

    Article • Pharmaceuticals, January 2024, MDPI AG

    Dr Paolo PB Baldo

  6. How will the identification and therapeutic intervention of genetic targets in oncology evolve for future therapy?

    Article • Expert Opinion on Therapeutic Targets, December 2023, Taylor & Francis

    Dr Paolo PB Baldo

  7. Toxicity Derived from Interaction between Natural Compounds and Cancer Therapeutic Drugs Metabolized by CYP3A4: Lessons Learned from Two Clinical Case Reports

    Article • International Journal of Molecular Sciences, November 2023, MDPI AG

    Dr Paolo PB Baldo

  8. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data

    Article • Cancer Medicine, August 2022, Wiley

    Dr Marco Chiumente, Dr Paolo PB Baldo

  9. Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice

    Article • International Journal of Molecular Sciences, March 2022, MDPI AG

    Dr Paolo PB Baldo

  10. Pharmacovigilance of anti-cancer medicines: opportunities and challenges

    Article • Expert Opinion on Drug Safety, June 2020, Taylor & Francis

    Dr Paolo PB Baldo

  11. Ensuring the best care to cancer patients in the COVID-19 pandemic era: insights and challenges.

    Article • May 2020, Wiley

    Dr Paolo PB Baldo

  12. Safety Profiles and Pharmacovigilance Considerations for Recently Patented / Approved Anticancer Drugs

    Article • Recent Patents on Anti-Cancer Drug Discovery, November 2019, Bentham Science Publishers

    Dr Paolo PB Baldo

  13. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer

    Article • Recent Patents on Anti-Cancer Drug Discovery, November 2019, Bentham Science Publishers

    Dr Paolo PB Baldo

  14. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma

    Article • Recent Patents on Anti-Cancer Drug Discovery, November 2019, Bentham Science Publishers

    Dr Paolo PB Baldo

  15. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer

    Article • Recent Patents on Anti-Cancer Drug Discovery, November 2019, Bentham Science Publishers

    Dr Paolo PB Baldo

  16. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review

    Article • Advances in Therapy, September 2018, Springer Science + Business Media

    Dr Paolo PB Baldo

  17. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies

    Article • International Journal of Clinical Pharmacy, August 2018, Springer Science + Business Media

    Dr Paolo PB Baldo

  18. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology

    Article • International Journal of Clinical Pharmacy, August 2018, Springer Science + Business Media

    Dr Paolo PB Baldo

  19. Pharmacovigilance in oncology

    Article • International Journal of Clinical Pharmacy, August 2018, Springer Science + Business Media

    Dr Paolo PB Baldo

  20. An historical overview over Pharmacovigilance

    Article • International Journal of Clinical Pharmacy, June 2018, Springer Science + Business Media

    Dr Paolo PB Baldo

  21. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance

    Article • International Journal of Clinical Pharmacy, May 2018, Springer Science + Business Media

    Dr Paolo PB Baldo

  22. Amatuximab and novel agents targeting mesothelin for solid tumors

    Article • OncoTargets and Therapy, November 2017, Dove Medical Press

    Dr Paolo PB Baldo

  23. Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations

    Article • Oncology and Therapy, August 2016, Springer Science + Business Media

    Dr Paolo PB Baldo

  24. Toxicities and Adverse Drug Reactions Experienced During Anticancer Treatment: It Is Desirable to Consider the Problem Within the International System of Pharmacovigilance

    Article • Journal of Clinical Oncology, July 2015, American Society of Clinical Oncology (ASCO)

    Dr Paolo PB Baldo

  25. Patient-Centered Cancer Care Programs in Italy: Benchmarking Global Patient Education Initiatives

    Article • Journal of Cancer Education, March 2015, Springer Science + Business Media

    Dr Paolo PB Baldo

  26. Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adults

    Article • Cochrane Database of Systematic Reviews, March 2015, Wiley

    Dr Paolo PB Baldo

  27. Erlotinib for advanced pancreatic cancer

    Article • Cochrane Database of Systematic Reviews, January 2015, Wiley

    Dr Paolo PB Baldo

  28. Pharmacovigilance in oncology: evaluation of current practice and future perspectives

    Article • Journal of Evaluation in Clinical Practice, June 2014, Wiley

    Dr Paolo PB Baldo

  29. Safety and efficacy evaluation of albumin-bound paclitaxel

    Article • Expert Opinion on Drug Safety, February 2014, Informa Healthcare

    Dr Paolo PB Baldo

  30. Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives

    Article • Current Cancer Drug Targets, January 2011, Bentham Science Publishers

    Dr Paolo PB Baldo

  31. Interferon-alpha for maintenance of follicular lymphoma

    Article • Cochrane Database of Systematic Reviews, January 2010, Wiley

    Dr Paolo PB Baldo

  32. Incidence of Palmar-Plantar Erythrodysesthesia in Pretreated and Unpretreated Patients Receiving Pegylated Liposomal Doxorubicin

    Article • Tumori Journal, November 2009, SAGE Publications

    Dr Paolo PB Baldo

  33. mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

    Article • Current Cancer Drug Targets, December 2008, Bentham Science Publishers

    Dr Paolo PB Baldo

  34. A centralized Pharmacy Unit for cytotoxic drugs in accordance with Italian legislation

    Article • Journal of Evaluation in Clinical Practice, April 2007, Wiley

    Dr Paolo PB Baldo

  35. Antidepressants for patients with tinnitus

    Article • October 2006, Wiley

    Dr Paolo PB Baldo

  36. Interferon-alpha for follicular lymphoma

    Article • January 2004, Wiley

    Dr Paolo PB Baldo